Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

Clinical trial NCT05156970 · COMPLETED

Trial details

NCT number

NCT05156970

Sponsor

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Status

COMPLETED

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2021-06-24

Primary completion

2024-06-24

Enrollment

81

View on ClinicalTrials.gov